Table 1.
Quantitative video intensity for ultrasound contrast agent targeted with isotype control antibody (UCAIGg) and anti-VEGFR2 monoclonal antibody (UCAVEGFR2)
| Normal thyroid (n.4) | Hyperplasia/Benign nodules (n.5) | Thyroid carcinoma (n.7) | |
|---|---|---|---|
| Video intensity UCAIGg |
|
||
| Video intensity difference |
11.3 (9.4-14.7) |
12.2 (8.5-19.6) |
19.4 (11.4-22.6) |
| Video intensity UCAVEGFR2 |
|
||
| Video intensity difference | 10.9 (10.3-14.9) | 13.3 (10.8-15.8) | 30.1 (25.1-35.6)* § |
* Statistical significant difference between Thyroid carcinoma and normal thyroid or Hyperplasia/benign nodules p<0.05.
§ Statistical significant difference between UCA targeted with anti-VEGFR2 monoclonal antibody and isotype control antibody p=0.0156.